(转化医学国家重大科技基础设施 北京协和)-北京市东城区帅府园一号，100730
(疑难重症及罕见病全国重点实验室)-北京市大兴区榆垡镇今荣大街73号，102602
服务热线:010-69150000
Wen X, Xu P, Zeng X, et al,. Development of [177Lu]Lu‑LNC1003 forradioligand therapy of prostate cancer with a moderate level of PSMA expression.European Journal of Nuclear Medicine and Molecular Imaging, 2023Jul;50(9):2846-2860.
时间：2024.04.22 发布来源：本站原创
Xuejun Wen,Pengfei Xu, Xinying Zeng, Jia Liu, Chao Du, Xueyuan Zeng, Xingxing Cheng, XueqiWang, Yuanyuan Liang, Tianzhi Zhao, Hongzhang Yang, Huifeng Li, Lingxin Meng,Jianyang Fang, Hongwu Liu, Zijian Zhou, Jingjing Zhang*, Xianzhong Zhang*, Zhide Guo* & Xiaoyuan Chen*. Development of [177Lu]Lu‑LNC1003 forradioligand therapy of prostate cancer with a moderate level of PSMA expression.European Journal of Nuclear Medicine and Molecular Imaging, 2023Jul;50(9):2846-2860. doi: 10.1007/s00259-023-06229-w. Epub 2023 Apr 25.